{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:43:34Z","timestamp":1789249414721,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015763","name":"University of Szeged","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015763","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Sodium-glucose cotransporter 2 inhibitors, such as empagliflozin (EMPA), have been increasingly investigated for their potential neuroprotective properties, but their overall metabolic impact in Parkinson\u2019s disease (PD) remains incompletely understood. Using a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD, we investigated the effect of EMPA on tryptophan (TRP) metabolism, neurotransmitter levels and antioxidant markers in the striatum. Targeted ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC\u2013MS\/MS) was used for metabolite quantification. Pairwise group differences were assessed using Welch\u2019s two-sample\n                    <jats:italic>t<\/jats:italic>\n                    -test, with false discovery rate correction, and multivariate analyses were applied for exploratory pattern recognition. EMPA treatment significantly enhanced the neuroprotective arm of the kynurenine pathway (KP), increasing kynurenic acid (KA), anthranilic acid (AA), xanthurenic acid (XA) and the corresponding enzymatic activity ratios in MPTP-induced PD animals. The selective elevation of the KA\/TRP ratio without a corresponding change in KYN\/TRP suggests that EMPA acts specifically on the KAT-mediated neuroprotective branch, potentially through restoration of astrocytic redox state in the striatum, rather than through generalized modulation of IDO\/TDO-driven TRP catabolism. In Sirtuin3 knock-out (S3KO) mice, EMPA reduced 3-hydroxykynurenine (3OHK) levels and the Oxidative Stress Index (3OHK\/(KA\u2009+\u2009AA\u2009+\u2009XA)), and improved glutathione redox status, as reflected by reduced GSSG levels and an improved GSH\/GSSG ratio. These results demonstrate that EMPA exerts significant neurometabolic effects in a mouse model of PD, shifting KP flux towards neuroprotective metabolites and improving redox homeostasis\u2014particularly in the context of mitochondrial dysfunction modelled by Sirtuin3 deficiency. Future studies extending these findings to additional experimental models and clinical settings will be essential to fully elucidate the translational potential of EMPA in neurodegeneration.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-55891-1","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:26:58Z","timestamp":1780561618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeted metabolomics to assess positive effects of empagliflozin in a Parkinson\u2019s disease model: focused on the kynurenine pathway and oxidative stress"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3280-0818","authenticated-orcid":false,"given":"Istv\u00e1n","family":"L\u00e9n\u00e1rt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3652-0852","authenticated-orcid":false,"given":"Orsolya","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0596-2191","authenticated-orcid":false,"given":"Kinga","family":"Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0091-3558","authenticated-orcid":false,"given":"Csaba","family":"Bereczki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3591-6054","authenticated-orcid":false,"given":"P\u00e9ter","family":"Monostori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5389-3266","authenticated-orcid":false,"given":"P\u00e9ter","family":"Kliv\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9166-1212","authenticated-orcid":false,"given":"Zsolt","family":"Galla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"55891_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","volume":"403","author":"Y Ben-Shlomo","year":"2024","unstructured":"Ben-Shlomo, Y. et al. The epidemiology of Parkinson\u2019s disease. Lancet 403, 283\u2013292. https:\/\/doi.org\/10.1016\/S0140-6736(23)01419-8 (2024).","journal-title":"Lancet"},{"key":"55891_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1720621","volume":"2016","author":"L Xu","year":"2016","unstructured":"Xu, L. & Pu, J. Alpha-synuclein in Parkinson\u2019s disease: from pathogenetic dysfunction to potential clinical application. Parkinsons Dis 2016, 1720621. https:\/\/doi.org\/10.1155\/2016\/1720621 (2016).","journal-title":"Parkinsons Dis"},{"key":"55891_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/neup.12812","volume":"42","author":"CJ Choong","year":"2022","unstructured":"Choong, C. J. & Mochizuki, H. Neuropathology of \u03b1-synuclein in Parkinson\u2019s disease. Neuropathology 42, 93\u2013103. https:\/\/doi.org\/10.1111\/neup.12812 (2022).","journal-title":"Neuropathology"},{"key":"55891_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-016-0060-6","volume":"5","author":"Q Hu","year":"2016","unstructured":"Hu, Q. & Wang, G. Mitochondrial dysfunction in Parkinson\u2019s disease. Transl Neurodegener 5, 14. https:\/\/doi.org\/10.1186\/s40035-016-0060-6 (2016).","journal-title":"Transl Neurodegener"},{"key":"55891_CR5","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s12035-013-8554-z","volume":"49","author":"G Anderson","year":"2014","unstructured":"Anderson, G. & Maes, M. Neurodegeneration in Parkinson\u2019s Disease: Interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins. Mol Neurobiol 49, 771\u2013783. https:\/\/doi.org\/10.1007\/s12035-013-8554-z (2014).","journal-title":"Mol Neurobiol"},{"key":"55891_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/jnc.14104","volume":"142","author":"JF Havelund","year":"2017","unstructured":"Havelund, J. F. et al. Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia. J. Neurochem. 142, 756\u2013766. https:\/\/doi.org\/10.1111\/jnc.14104 (2017).","journal-title":"J. Neurochem."},{"key":"55891_CR7","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1002\/mds.28202","volume":"35","author":"PL Heilman","year":"2020","unstructured":"Heilman, P. L. et al. Tryptophan metabolites are associated with symptoms and nigral pathology in Parkinson\u2019s disease. Mov. Disord. 35, 2028\u20132037. https:\/\/doi.org\/10.1002\/mds.28202 (2020).","journal-title":"Mov. Disord."},{"key":"55891_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2024.151418","volume":"103","author":"T Kondo","year":"2024","unstructured":"Kondo, T. et al. Neuroimmune modulation by tryptophan derivatives in neurological and inflammatory disorders. Eur. J. Cell Biol. 103, 151418. https:\/\/doi.org\/10.1016\/j.ejcb.2024.151418 (2024).","journal-title":"Eur. J. Cell Biol."},{"key":"55891_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/11786469241248287","volume":"17","author":"BS Summers","year":"2024","unstructured":"Summers, B. S. et al. A review of the evidence for tryptophan and the kynurenine pathway as a regulator of stem cell niches in health and disease. Int J Tryptophan Res 17, 11786469241248287. https:\/\/doi.org\/10.1177\/11786469241248287 (2024).","journal-title":"Int J Tryptophan Res"},{"key":"55891_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13111166","author":"Y Hou","year":"2023","unstructured":"Hou, Y., Li, J. & Ying, S. Tryptophan metabolism and gut microbiota: a novel regulatory axis integrating the microbiome, immunity, and cancer. Metabolites https:\/\/doi.org\/10.3390\/metabo13111166 (2023).","journal-title":"Metabolites"},{"key":"55891_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.neuropharm.2016.03.024","volume":"112","author":"MD Lovelace","year":"2017","unstructured":"Lovelace, M. D. et al. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. Neuropharmacology 112, 373\u2013388. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.03.024 (2017).","journal-title":"Neuropharmacology"},{"key":"55891_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/jad-2011-110131","volume":"24","author":"I Plang\u00e1r","year":"2011","unstructured":"Plang\u00e1r, I., Z\u00e1dori, D., Kliv\u00e9nyi, P., Toldi, J. & V\u00e9csei, L. Targeting the kynurenine pathway-related alterations in Alzheimer\u2019s disease: a future therapeutic strategy. J. Alzheimers Dis. 24, 199\u2013209. https:\/\/doi.org\/10.3233\/jad-2011-110131 (2011).","journal-title":"J. Alzheimers Dis."},{"key":"55891_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2478\/v10039-010-0023-6","volume":"55","author":"E Gulaj","year":"2010","unstructured":"Gulaj, E., Pawlak, K., Bien, B. & Pawlak, D. Kynurenine and its metabolites in Alzheimer\u2019s disease patients. Adv. Med. Sci. 55, 204\u2013211. https:\/\/doi.org\/10.2478\/v10039-010-0023-6 (2010).","journal-title":"Adv. Med. Sci."},{"key":"55891_CR14","doi-asserted-by":"publisher","first-page":"9772","DOI":"10.3390\/ijms16059772","volume":"16","author":"Z Boh\u00e1r","year":"2015","unstructured":"Boh\u00e1r, Z., Toldi, J., F\u00fcl\u00f6p, F. & V\u00e9csei, L. Changing the face of kynurenines and neurotoxicity: therapeutic considerations. Int. J. Mol. Sci. 16, 9772\u20139793. https:\/\/doi.org\/10.3390\/ijms16059772 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"55891_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136737","author":"T Behl","year":"2021","unstructured":"Behl, T. et al. The footprint of Kynurenine Pathway in neurodegeneration: Janus-faced role in Parkinson\u2019s Disorder and therapeutic implications. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22136737 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"55891_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cns.13768","volume":"28","author":"A Ostapiuk","year":"2022","unstructured":"Ostapiuk, A. & Urbanska, E. M. Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?. CNS. Neurosci. Ther. 28, 19\u201335. https:\/\/doi.org\/10.1111\/cns.13768 (2022).","journal-title":"CNS. Neurosci. Ther."},{"key":"55891_CR17","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/716859","volume":"2011","author":"A Zinger","year":"2011","unstructured":"Zinger, A., Barcia, C., Herrero, M. T. & Guillemin, G. J. The involvement of neuroinflammation and kynurenine pathway in Parkinson\u2019s disease. Parkinsons Dis. 2011, 716859. https:\/\/doi.org\/10.4061\/2011\/716859 (2011).","journal-title":"Parkinsons Dis."},{"key":"55891_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.997240","volume":"13","author":"M Fathi","year":"2022","unstructured":"Fathi, M. et al. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer\u2019s disease, Parkinson\u2019s disease, and Huntington\u2019s disease: a systematic review and meta-analysis. Front. Immunol. 13, 997240. https:\/\/doi.org\/10.3389\/fimmu.2022.997240 (2022).","journal-title":"Front. Immunol."},{"key":"55891_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2023.2225800","volume":"38","author":"P Chen","year":"2023","unstructured":"Chen, P. & Geng, X. Research progress on the kynurenine pathway in the prevention and treatment of Parkinson\u2019s disease. J. Enzyme Inhib. Med. Chem. 38, 2225800. https:\/\/doi.org\/10.1080\/14756366.2023.2225800 (2023).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"55891_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nprot.2006.342","volume":"2","author":"V Jackson-Lewis","year":"2007","unstructured":"Jackson-Lewis, V. & Przedborski, S. Protocol for the MPTP mouse model of Parkinson\u2019s disease. Nat. Protoc. 2, 141\u2013151. https:\/\/doi.org\/10.1038\/nprot.2006.342 (2007).","journal-title":"Nat. Protoc."},{"key":"55891_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3233\/jpd-2011-11023","volume":"1","author":"GE Meredith","year":"2011","unstructured":"Meredith, G. E. & Rademacher, D. J. MPTP mouse models of Parkinson\u2019s disease: an update. J. Parkinsons Dis. 1, 19\u201333. https:\/\/doi.org\/10.3233\/jpd-2011-11023 (2011).","journal-title":"J. Parkinsons Dis."},{"key":"55891_CR22","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00018-011-0850-z","volume":"69","author":"G Mud\u00f2","year":"2012","unstructured":"Mud\u00f2, G. et al. Transgenic expression and activation of PGC-1\u03b1 protect dopaminergic neurons in the MPTP mouse model of Parkinson\u2019s disease. Cell. Mol. Life Sci. 69, 1153\u20131165. https:\/\/doi.org\/10.1007\/s00018-011-0850-z (2012).","journal-title":"Cell. Mol. Life Sci."},{"key":"55891_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-024-04258-x","volume":"50","author":"Y Gao","year":"2024","unstructured":"Gao, Y. et al. Atractylenolide-I attenuates MPTP\/MPP(+)\u2011mediated oxidative stress in Parkinson\u2019s disease through SIRT1\/PGC\u20111\u03b1\/Nrf2 axis. Neurochem. Res. 50, 18. https:\/\/doi.org\/10.1007\/s11064-024-04258-x (2024).","journal-title":"Neurochem. Res."},{"key":"55891_CR24","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1002\/tox.24275","volume":"39","author":"CF Jhuo","year":"2024","unstructured":"Jhuo, C. F., Chen, C. J., Tzen, J. T. C. & Chen, W. Y. Teaghrelin protected dopaminergic neurons in MPTP-induced Parkinson\u2019s disease animal model by promoting PINK1\/Parkin-mediated mitophagy and AMPK\/SIRT1\/PGC1-\u03b1-mediated mitochondrial biogenesis. Environ. Toxicol. 39, 4022\u20134034. https:\/\/doi.org\/10.1002\/tox.24275 (2024).","journal-title":"Environ. Toxicol."},{"key":"55891_CR25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"15","author":"H Zhou","year":"2018","unstructured":"Zhou, H. et al. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 15, 335\u2013346. https:\/\/doi.org\/10.1016\/j.redox.2017.12.019 (2018).","journal-title":"Redox Biol."},{"key":"55891_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1197061","volume":"2022","author":"M Ala","year":"2022","unstructured":"Ala, M., Khoshdel, M. R. F. & Dehpour, A. R. Empagliflozin enhances autophagy, mitochondrial biogenesis, and antioxidant defense and ameliorates renal ischemia\/reperfusion in nondiabetic rats. Oxid. Med. Cell. Longev. 2022, 1197061. https:\/\/doi.org\/10.1155\/2022\/1197061 (2022).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"55891_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237213","author":"A Pawlos","year":"2021","unstructured":"Pawlos, A., Broncel, M., Wo\u017aniak, E. & Gorzelak-Pabi\u015b, P. Neuroprotective effect of SGLT2 inhibitors. Molecules https:\/\/doi.org\/10.3390\/molecules26237213 (2021).","journal-title":"Molecules"},{"key":"55891_CR28","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jsps.2022.03.005","volume":"30","author":"S Ahmed","year":"2022","unstructured":"Ahmed, S., El-Sayed, M. M., Kandeil, M. A. & Khalaf, M. M. Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of \u03b1-synuclein and Parkin levels in rotenone-induced Parkinson\u2019s disease in rats. Saudi Pharm. J. 30, 863\u2013873. https:\/\/doi.org\/10.1016\/j.jsps.2022.03.005 (2022).","journal-title":"Saudi Pharm. J."},{"key":"55891_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121258","volume":"312","author":"HH Mousa","year":"2023","unstructured":"Mousa, H. H., Sharawy, M. H. & Nader, M. A. Empagliflozin enhances neuroplasticity in rotenone-induced parkinsonism: role of BDNF, CREB and Npas4. Life Sci. 312, 121258. https:\/\/doi.org\/10.1016\/j.lfs.2022.121258 (2023).","journal-title":"Life Sci."},{"key":"55891_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2021.122846","volume":"1179","author":"Z Galla","year":"2021","unstructured":"Galla, Z. et al. Improved LC-MS\/MS method for the determination of 42 neurologically and metabolically important molecules in urine. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1179, 122846. https:\/\/doi.org\/10.1016\/j.jchromb.2021.122846 (2021).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"55891_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2020.461775","volume":"1635","author":"Z Galla","year":"2021","unstructured":"Galla, Z. et al. Simultaneous determination of 30 neurologically and metabolically important molecules: a sensitive and selective way to measure tyrosine and tryptophan pathway metabolites and other biomarkers in human serum and cerebrospinal fluid. J. Chromatogr. A 1635, 461775. https:\/\/doi.org\/10.1016\/j.chroma.2020.461775 (2021).","journal-title":"J. Chromatogr. A"},{"key":"55891_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030945","author":"H Polyak","year":"2023","unstructured":"Polyak, H. et al. The Tryptophan-Kynurenine Metabolic System is suppressed in Cuprizone-induced model of demyelination simulating progressive Multiple Sclerosis. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines11030945 (2023).","journal-title":"Biomedicines"},{"key":"55891_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03027-x","volume":"21","author":"NA Yousri","year":"2023","unstructured":"Yousri, N. A., Albagha, O. M. E. & Hunt, S. C. Integrated epigenome, whole genome sequence and metabolome analyses identify novel multi-omics pathways in type 2 diabetes: a Middle Eastern study. BMC Med. 21, 347. https:\/\/doi.org\/10.1186\/s12916-023-03027-x (2023).","journal-title":"BMC Med."},{"key":"55891_CR34","doi-asserted-by":"publisher","DOI":"10.1201\/9781315119472","volume-title":"Modern Directional Statistics","author":"C Ley","year":"2017","unstructured":"Ley, C. & Verdebout, T. Modern Directional Statistics ed. 1st. (Chapman & Hall\/CRC, 2017).","edition":"ed. 1st"},{"key":"55891_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/9780470434697","volume-title":"Robust Statistics","author":"PJ Huber","year":"2009","unstructured":"Huber, P. J. & Ronchetti, E. M. Robust Statistics ed. 2nd. (Wiley, 2009).","edition":"ed. 2nd"},{"key":"55891_CR36","volume-title":"Statistical Analysis with Missing Data","author":"RJA Little","year":"2019","unstructured":"Little, R. J. A. & Rubin, D. B. Statistical Analysis with Missing Data ed. 3nd. (Wiley, 2019).","edition":"ed. 3nd"},{"key":"55891_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.728986","volume":"12","author":"D Juchnowicz","year":"2021","unstructured":"Juchnowicz, D. et al. Oxidative stress biomarkers as a predictor of stage illness and clinical course of schizophrenia. Front. Psychiatry 12, 728986. https:\/\/doi.org\/10.3389\/fpsyt.2021.728986 (2021).","journal-title":"Front. Psychiatry"},{"key":"55891_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jpsychires.2023.05.022","volume":"162","author":"N Polat","year":"2023","unstructured":"Polat, N. et al. Comparison of oxidative stress parameters, thiol-disulfide homeostasis, and pro-inflammatory cytokines levels in patients with bipolar disorder and their first-degree relatives. J. Psychiatr. Res. 162, 103\u2013112 (2023).","journal-title":"J. Psychiatr. Res."},{"key":"55891_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1017\/neu.2018.33","volume":"31","author":"E Kabadayi Sahin","year":"2019","unstructured":"Kabadayi Sahin, E. et al. A comprehensive study of oxidative stress in patients with somatic symptom disorder. Acta Neuropsychiatr. 31, 100\u2013105. https:\/\/doi.org\/10.1017\/neu.2018.33 (2019).","journal-title":"Acta Neuropsychiatr."},{"key":"55891_CR40","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1111\/dom.15943","volume":"26","author":"J Guo","year":"2024","unstructured":"Guo, J. et al. Sodium-glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real-world patients with type 2 diabetes. Diabetes Obes. Metab. 26, 5727\u20135736. https:\/\/doi.org\/10.1111\/dom.15943 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"55891_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41401-023-01144-0","volume":"45","author":"W Yu","year":"2024","unstructured":"Yu, W. et al. SGLT2 inhibitor empagliflozin alleviates cardiac remodeling and contractile anomalies in a FUNDC1-dependent manner in experimental Parkinson\u2019s disease. Acta Pharmacol. Sin. 45, 87\u201397. https:\/\/doi.org\/10.1038\/s41401-023-01144-0 (2024).","journal-title":"Acta Pharmacol. Sin."},{"key":"55891_CR42","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/ejhf.3192","volume":"26","author":"N Wood","year":"2024","unstructured":"Wood, N. et al. Sodium-glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction. Eur. J. Heart Fail. 26, 925\u2013935. https:\/\/doi.org\/10.1002\/ejhf.3192 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"55891_CR43","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2174\/1570159X20666220922153221","volume":"21","author":"LB Martins","year":"2023","unstructured":"Martins, L. B., Silveira, A. L. M. & Teixeira, A. L. The involvement of Kynurenine pathway in neurodegenerative diseases. Curr. Neuropharmacol. 21, 260\u2013272. https:\/\/doi.org\/10.2174\/1570159X20666220922153221 (2023).","journal-title":"Curr. Neuropharmacol."},{"key":"55891_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137144","author":"M Fujikawa","year":"2024","unstructured":"Fujikawa, M., Ueda, M. & Maruyama, K. Role of Kynurenine and its derivatives in the neuroimmune system. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms25137144 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"55891_CR45","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3390\/vaccines3030703","volume":"3","author":"JC Mbongue","year":"2015","unstructured":"Mbongue, J. C. et al. The role of Indoleamine 2, 3-Dioxygenase in immune suppression and autoimmunity. Vaccines 3, 703\u2013729 (2015).","journal-title":"Vaccines"},{"key":"55891_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.cyto.2006.07.007","volume":"35","author":"CM Robinson","year":"2006","unstructured":"Robinson, C. M., Hale, P. T. & Carlin, J. M. NF-kappa B activation contributes to Indoleamine Dioxygenase transcriptional synergy induced by IFN-gamma and tumor necrosis factor-alpha. Cytokine 35, 53\u201361. https:\/\/doi.org\/10.1016\/j.cyto.2006.07.007 (2006).","journal-title":"Cytokine"},{"key":"55891_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2025.103230","volume":"98","author":"G Jenei","year":"2026","unstructured":"Jenei, G. et al. Expression of Kynurenine Aminotransferase-2 in different mouse brain-derived cells: a comprehensive study in cell cultures. Tissue Cell 98, 103230. https:\/\/doi.org\/10.1016\/j.tice.2025.103230 (2026).","journal-title":"Tissue Cell"},{"key":"55891_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12111999","volume":"12","author":"J-E Park","year":"2023","unstructured":"Park, J.-E., Leem, Y.-H., Park, J.-S., Kim, S.-E. & Kim, H.-S. Astrocytic Nrf2 mediates the neuroprotective and anti-inflammatory effects of Nootkatone in an MPTP-induced Parkinson\u2019s disease mouse model. Antioxidants 12, 1999 (2023).","journal-title":"Antioxidants"},{"key":"55891_CR49","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1093\/hmg\/ddx100","volume":"26","author":"H Shi","year":"2017","unstructured":"Shi, H. et al. Sirt3 protects dopaminergic neurons from mitochondrial oxidative stress. Hum. Mol. Genet. 26, 1915\u20131926. https:\/\/doi.org\/10.1093\/hmg\/ddx100 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"55891_CR50","doi-asserted-by":"publisher","first-page":"18025","DOI":"10.1041\/s41598-023-45390-y","volume":"13","author":"R Kawakami","year":"2023","unstructured":"Kawakami, R. et al. Empagliflozin induces the transcriptional program for nutrient homeostasis in skeletal muscle in normal mice. Sci Rep 13, 18025. https:\/\/doi.org\/10.1041\/s41598-023-45390-y (2023).","journal-title":"Sci Rep"},{"key":"55891_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11050799","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Empagliflozin-enhanced antioxidant defense attenuates lipotoxicity and protects hepatocytes by promoting FoxO3a- and Nrf2-mediated nuclear translocation via the CAMKK2\/AMPK pathway. Antioxidants https:\/\/doi.org\/10.3390\/antiox11050799 (2022).","journal-title":"Antioxidants"},{"key":"55891_CR52","doi-asserted-by":"publisher","first-page":"8768","DOI":"10.1007\/s12035-025-04800-0","volume":"62","author":"J Ma","year":"2025","unstructured":"Ma, J. et al. Empagliflozin inhibits neuronal ferroptosis induced by oxygen-glucose deprivation\/reoxygenation by activating the Nrf2\/HO-1 pathway. Mol. Neurobiol. 62, 8768\u20138781. https:\/\/doi.org\/10.1007\/s12035-025-04800-0 (2025).","journal-title":"Mol. Neurobiol."},{"key":"55891_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193107","author":"M Heimke","year":"2022","unstructured":"Heimke, M., Lenz, F., Rickert, U., Lucius, R. & Cossais, F. Anti-inflammatory properties of the SGLT2 inhibitor Empagliflozin in activated primary microglia. Cells https:\/\/doi.org\/10.3390\/cells11193107 (2022).","journal-title":"Cells"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55891-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55891-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55891-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:45:56Z","timestamp":1786668356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55891-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55891"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55891-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8658213\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This investigation conformed to the EU Directive 2010\/63\/EU and was approved by the regional Animal Research Ethics Committee of Csongr\u00e1d County (Project License: XI.\/167\/2022) and the University of Szeged in Hungary.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"25468"}}